Back to search results
NCT04047784

Pilot Study to Evaluate the Role of EBUS in the Diagnosis of Acute PE in Critically Ill Patients

Enrolling by Invitation
NAAges 18+InterventionalDiagnostic
University of California, Los Angeles
~60 participants
Updated 2026-05-06 on ClinicalTrials.gov
What's tested:Endobronchial ultrasound (EBUS)

At a glance

Recruiting sites
0 of 2 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
CT angiogram results (if obtained)
Measured over 2 years
+6 more outcomes measured

Conditions

Acute Pulmonary Embolism

Explore related trials

Acute Pulmonary Embolism

Where it's being run

2 sites across 1 states
California2

Study leadership

  • Colleen L Channick, M.D. · PRINCIPAL_INVESTIGATOR · University of California, Los Angeles

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Patient ≥ 18 years of age.
The patient or patient's surrogate must understand and sign informed consent form (ICF).
Intubated patients in the intensive care unit (ICU) where there is a clinical concern for acute pulmonary embolism or a confirmed diagnosis for acute pulmonary embolism.
Patient ≥ 18 years of age.
The patient or patient's surrogate must understand and sign informed consent form (ICF).
Intubated patients undergoing clinical bronchoscopy, as determined by the treating physician.

Exclusion

Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
Endotracheal tube size less than 8.0 mm.
Contraindications to lidocaine.
Patient does not meet the requirements to undergo clinical bronchoscopy, as determined by the treating physician.
Endotracheal tube size less than 8.0 mm.
Contraindications to lidocaine.

What this trial measures

  • CT angiogram results (if obtained)2 years

    For patients who have had a chest CT for suspected PE, the investigators will obtain a copy of the participant's chest CT for suspected PE report.

  • Patient treatment2 years

    For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but will report the number of positive and negative studies. Patient treatment will be reported as: * Catheter Directed Lysis * Heparin Drip * Surgical Embolectomy * Thrombolysis * No Treatment for Pulmonary Embolism (PE)

  • Patient outcome2 years

    For patients who are unable to have a CT, the investigators will not be able to determine true efficacy, but follow these patients for outcome and subsequent definitive diagnosis of venous thromboembolism. Subsequent patient outcome will be reported as: * Alive * Extended hospitalization * Intervention to prevent impairment or damage * Life-threatening condition * Disability * Death

  • Assess sensitivity and specificity of EBUS to visualize or exclude PE compared to the chest CT.2 years

    Ability for EBUS will be reported by its ability to identify each major branch and reporting what branched not identified as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other

  • Report any complications2 years

    Complications during or after the procedure will be reported as: * Airway Bleeding * Airway Injury * Hypotension as defined by \< 65 mmHg or need to escalate vasopressors * Hypoxia as defined by \< 90% * Other * None

  • Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify a clot.2 years

    Ability for EBUS will be reported by its ability to identify a clot and reporting the location of the clot as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other

  • Assess sensitivity and specificity of EBUS to visualize or exclude PE by its ability to identify flow around clot(s) present.2 years

    Ability for EBUS will be reported by its ability to identify flow around clot(s) present and reporting the location of the flow around clot(s) present as: * Main Pulmonary Artery (MPA) * Right Pulmonary Artery (RPA) * Truncus Anterior (TA) or Ascending Branch * Right Interlobar Artery or Descending Branch * Right Basal Trunk * Left Pulmonary Artery (LPA) * Left Interlobar Artery * Left Basal Trunk * Other